This article first appeared on GuruFocus .
Release Date: November 09, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Medicus Pharma Ltd ( NASDAQ:MDCX ) secured a worldwide license to CD228V, a clinical-stage antibody-drug conjugate from Pfizer, with Pfizer providing $2 million for development activities.
-
CD228V has a differentiated target and a substantial scientific foundation, with potential to achieve an objective response rate exceeding 30% in melanoma, a clinically meaningful benchmark.
-
The proposed SkinJet business combination at a $135 million pre-money valuation could unlock value for shareholders while allowing Medicus Pharma Ltd ( NASDAQ:MDCX ) to focus on precision oncology.
-
Medicus Pharma Ltd ( NASDAQ:MDCX ) raised approximately $42.5 million in equity and secured debt financing, netting $36.2 million after debt repayments, to support its transformation.
-
The company anticipates a substantial reduction in operating expenses in the coming quarters, reflecting capital-efficient drug development.
Negative Points
-
Medicus Pharma Ltd ( NASDAQ:MDCX ) reported a net loss of $35.9 million for the first nine months of 2026, an increase from $27.3 million in the prior year.
-
Operating expenses rose to $34.5 million from $26.6 million, including a $10 million acquired IP R&D charge related to the Pfizer agreement.
-
Cash and cash equivalents stood at only $5 million as of September 30, 2026, with total liabilities of $25 million, indicating potential liquidity concerns.
-
The proposed SkinJet business combination is subject to definitive agreements, financing, and closing conditions, with no assurance it will complete within the expected first half of 2027 timeframe.
-
Tavarelix programs are facing delays, including CMC manufacturing snags and pending FDA feedback, which could hinder partnership opportunities and product availability.
Q & A Highlights
Q: With regard to CD228V, when can investors expect the next clinical and regulatory milestones under the Pfizer collaboration? A: Dr. Faisal Mahmood, Chief Medical Officer, explained that Medicus is not starting from a blank sheet, citing the existing clinical foundation, manufacturing knowledge, and prior regulatory experience associated with the program. He said the immediate priority is to translate those advantages into an efficient development plan, which is being constructed now, with the goal of reaching the next meaningful clinical decision point as quickly and responsibly as possible. He noted the company is just under 60 days from completing the transaction and is still assimilating program details, but will move forward "from a running start."
Q: What would you consider a compelling proof-of-concept signal for CD228V in melanoma, and how could it inform expansion into other CD228-expressing solid tumors? A: Dr. Raza Bukhari, Executive Chairman and CEO, said review of data from 88 patients in the CGEN basket study, combined with Pfizer's reconstruction of the payload linker using the established vedotin platform, gives confidence that an objective response rate above 30% in melanoma is reasonably achievable. Dr. Mahmood added that the focus is on three pillars the differentiated CD228 target, the clinical experience from the predecessor molecule rather than preclinical models alone, and an established linker-payload platform. He stressed the plan is not an unfocused pan-tumor program but initially targets immunotherapy-resistant melanoma with substantial unmet need, with potential expansion into combinations with immunotherapy and tumor types such as squamous lung, esophageal, and head and neck cancer already built into the study.
Q: How much clinical data does Medicus have in hand for CD228V, and how does that shape the risk profile of the program? A: Dr. Bukhari said Medicus takes the baton with approximately 99 patient data points from the original CGEN study plus 11 patients from the CD228V program Pfizer initiated after reconstructing the molecule. He also cited expected detailed readouts from Bond Biotech, a Hong Kong-listed company he believes has completed roughly 30-plus patients in a Phase I dose-escalation study, as an additional confidence pointer. He characterized the asset as still early but not starting from scratch, adding that the objective is to "fail early" if necessary so the company can reshape its path, while remaining cautiously optimistic that a melanoma study could make a difference for patients who need it most.
Q: Will Medicus wait for the proposed SkinJet business combination to close before advancing SkinJet's clinical programs? A: Dr. Bukhari said Medicus will continue advancing progress toward the SkinJet 005 study in parallel while working to make the contemplated transaction a reality, so there is no delay cost. He estimated the budget to reach a potential NDA-enabling registrational study, assuming all scientific rigor and FDA thresholds are met, at no more than $3 million spread over the next two years. He noted Medicus has already made substantial investment of time and resources over the past two years to bring SkinJet to its current stage, which he said is maturing well.
Q: What kind of partnership is Medicus seeking for Tavarelix global, regional, or collaboration-based? A: Dr. Bukhari answered "all of the above," saying that on a go-forward basis Medicus sees Tavarelix's best value for shareholders in actively and concertedly pursuing partnering and collaborations to find the resources needed to advance those programs. He recapped design refinements since the August 2025 acquisition: the acute urinary retention relapse prevention study was reduced from an inherited 390-patient registrational study to a 126-patient study with a study-may-proceed in hand, and an advanced prostate cancer program is before the FDA, approaching the 45-day mark for feedback. He also noted CMC work on Tavarelix had to start from scratch and hit some snags outside the company's control, with product expected to become available sometime in the first quarter of next year, ideally as partnerships begin to materialize.
Q: What are the key terms of the Pfizer co-development and license agreement for CD228V? A: Dr. Bukhari said that on September 2, through wholly owned subsidiary Medicus Pharma, Inc. (doing business as Medicus Oncology), Medicus entered a co-development and license agreement with Pfizer for PF-08046031, or CD228V. Subject to retained rights and other provisions, Medicus holds an exclusive worldwide license to develop, manufacture, and commercialize the program, with authority over program execution including development, manufacturing, regulatory approval, and commercialization. Pfizer remains involved under the co-development framework, provided $2 million for development activities, and retains the right, without obligation, to elect to fund all or part of development beginning with the first pivotal trial.
Q: What is the scientific rationale behind CD228V and why is melanoma the initial focus? A: Dr. Bukhari explained that CD228V is a second-generation construct originating from CGEN and subsequently advanced by Pfizer. The earlier molecule, SGN-CD228A, generated preliminary clinical observations and insights into the target, safety, and biomarkers, while CD228V uses Pfizer's established vedotin linker-payload platform with changes to the linker and the amount of payload per antibody, designed to improve the balance between drug exposure, tolerability, and anti-tumor activity. He said the initial focus is melanoma, particularly disease that has relapsed, become refractory, or resisted immunotherapy, based on CD228 biology and available expression data, and that concentrating on a defined population allows a focused clinical question to guide future investment.
Q: What are the terms and timeline of the proposed SkinJet business combination? A: Dr. Bukhari said Medicus announced on November 4 that SkinJet entered a non-binding letter of intent with an undisclosed SPAC. The proposed combination contemplates a $135 million pre-money enterprise valuation for SkinJet with concurrent equity financing at closing to support the SkinJet 005 study in Gorlin syndrome and preparation and submission of a potential NDA. Under the proposed terms, the SPAC would acquire 100% of SkinJet in exchange for newly issued common shares of the combined company, with Medicus seeking to retain majority economic and voting ownership. Medicus currently anticipates completing the transaction in the first half of 2027, with no assurance that definitive agreements will be signed, financing secured, or the transaction closed on that timeframe or at all.
Q: What were the key financial results for the third quarter and first nine months of 2026? A: Karen Bonner, President and CFO, reported that during the
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
